Figure 1 - Voxzogo Treatment Improves Body Proportionality From Year 1 Through Year 4Source: Company dataFigure 2 - Real-World Data Show High Adherence to Voxzogo TreatmentSource: Company data; Wedbush researchFigure 3 - BMRN Continues to Pursue Major Additional Opportunites for VoxzogoSource: Comp
A director at Abbvie Inc sold/sold after exercising options 5,230 shares at 233.560USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Moody's Ratings (Moody's) assigned A2 ratings to the new senior unsecured notes issuance of AbbVie Inc. ("AbbVie"). There are no changes to AbbVie's existing ratings including the A2 senior unsecured rating and the Prime-1 short-term rating, or the stable outlook. Proceeds of the offering will pri...
Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent
A director at Bio-Techne Corp sold 1,954 shares at 59.105USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Moody's Ratings (Moody's) assigned a Baa1 rating to the new senior unsecured notes offering of Amgen Inc. ("Amgen"). There are no changes to Amgen's existing ratings including the Baa1 senior unsecured notes rating, (P)Baa1 senior unsecured shelf rating, (P)Baa1 senior unsecured medium term note pro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.